Retinitis Pigmentosa Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Retinitis Pigmentosa Disease Pipeline Drugs Assessment
Retinitis Pigmentosais a group of eye disorders which causes progressive degeneration of retina. In this case, peripheral vision gradually decreases and eventually lost in most cases and central vision is usually preserved until late in these conditions. Some forms of RP can be associated with deafness, obesity, kidney disease and other health issues.Retina Pigmentosa starts in childhood. Most of the people will lose much of their sight by early adulthood.
There are different types of RP such as Autosomal Recessive Retinitis Pigmentosa, Autosomal Dominant Retinitis Pigmentosa and X-Linked Retinitis Pigmentosa. RP is diagnosed by Ophthalmoscope, Visual Field Test, Electroretinigram, and Genetic Test. Generally RP is treated with Acetazolamide, vitamin A palmitate, if the condition get worse then retinal implant is recommended.
By Trial Phase, Retinitis Pigmentosa pipeline drugs are segmented as:
- Preclinical Trials
- Phase 1
- Phase 2
- Phase 3
- Phase 4
By Company, Retinitis Pigmentosa pipeline drugs are segmented as:
- Novartis Pharmaceuticals
- GenSight Biologics
- Applied Genetic Technologies Corp
- Neurotech Pharmaceuticals
- QLT Inc.
- Astellas Pharma Inc
- Retina Implant AG
By Treatment, Retinitis Pigmentosa pipeline drugs are segmented as:
- Gene Therapy
- Gene Specific Therapy
- Gene Independent Therapy
- Ciliary neurotrophic factor (CNTF)
- Brimonidine tartrate
- Recombinant human nerve growth factor (hNGF)
- Human retinal progenitor cells.
- Tissue Transplantation
- Transcorneal electrical stimulation (TES)
- Artificial retina implants
By Route of Administration, Retinitis Pigmentosa pipeline drugs are segmented as:
- In March 2017, Nightstar in collaboration with Professor Robert MacLaren (Oxford team) and Professor Paulo Stanga started a Phase I/II clinical trial of gene therapy for X-linked Retinitis Pigmentosa to investigate the safety, tolerability and efficacy of a retinal gene therapy with an adeno-associated viral (AAV) vector encoding the defective gene Retinitis Pigmentosa GTPaseRegulater (RPGR)
- In November 2015, RetroSense commenced Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 a potential optogenetictherapyin Patients with Advanced Retinitis Pigmentosa (RP), In August 2016 RetroSense Therapeutics received patent protection for the methods of restoring or improving vision using optogenetic approaches in USA. In September 2016, Allergan acquired RST 001 from RetroSense Therapeutics
Retinitis Pigmentosa Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Retinitis Pigmentosa treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Retinitis Pigmentosa disease pipeline drugs development. This report studies the dynamics of the Retinitis Pigmentosa Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Retinitis Pigmentosa disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Key Features of the Report:
- Provides the information related to universities and research institutes working in the therapeutics development
- Report comprehensively covers the all active and discontinued studies
- Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
- Presents the prominent targets for drug development in each stage of clinical trial
- Provides the in-depth analysis on the each drug candidates in the clinical trial phases